Monoclonal antibody treatments for rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1257-1272

  Bossaller, Lukas ^a   Rothe, Achim ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Neurological Therapy Center   (Germany)

Author keywords

Antibody engineering; Biologics; Danger associated molecular pattern; Immunotherapy; Inflammasome; Interleukin 1 family cytokines; Recombinant DNA technology monoclonal antibody; Rheumatoid arthritis

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; ABATACEPT; ADALIMUMAB; AIN 4570; ALX 0061; ALX 0141; ATACICEPT; BELIMUMAB; BR 3FC; BRODALUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CLAZAKIZUMAB; DEKAVIL; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; F 8IL 10; GOLIMUMAB; INFLIXIMAB; IXEKIZUMAB; OCRELIZUMAB; OFATUMUMAB; OPG FC; OTELIXIZUMAB; OZORALIZUMAB; PLACULUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SARILUMAB; SECUKINUMAB; SIRUKUMAB; TABALUMAB; TACI FC; TOCILIZUMAB; TRU 015; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANOLIMUMAB;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE EROSION; CINCA SYNDROME; DISEASE COURSE; DRUG HALF LIFE; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; HISTONE ACETYLATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE ACTIVATION; MUCKLE WELLS SYNDROME; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN ENGINEERING; PSORIATIC ARTHRITIS; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 84881513403     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.811230     Document Type: Review

References (119)

1. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36(12): 1681-90 (Pubitemid 23360007)
2. Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 2010; 185(2): 791-4
3. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7(9): 715-25 (Pubitemid 47327396)
4. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 2006; 1(4): 2048-60 (Pubitemid 46773329)
5. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24(10): 1241-52 (Pubitemid 44564769)
6. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23(9): 1126-36 (Pubitemid 41486394)
7. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008; 22(5): 315-29
8. Brocchini S, Balan S, Godwin A, et al. PEGylation of native disulfide bonds in proteins. Nat Protoc 2006; 1(5): 2241-52
9. Hosse RJ, Rothe A, Power BE. A new generation of protein display scaffolds for molecular recognition. Protein Sci 2006; 15(1): 14-27 (Pubitemid 43004229)
10. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63(9): 1062-8 (Pubitemid 39120355)
11. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337(3): 141-7 (Pubitemid 27306284)
12. Wang H, Marsters SA, Baker T, et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2(7): 632-7 (Pubitemid 32677631)
13. van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63(7): 1782-92
14. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9(10): 767-74
15. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23(9): 1117-25 (Pubitemid 41486393)
16. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23(9): 1105-16 (Pubitemid 41486392)
17. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. Faseb J 2006; 20(10): 1599-610 (Pubitemid 44943797)
18. Lipovsek D, Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004; 290(1-2): 51-67 (Pubitemid 38917130)
19. Marks JD. Antibody affinity maturation by chain shuffling. Methods Mol Biol 2004; 248: 327-43
20. Valjakka J, Hemminki A, Niemi S, et al. Crystal structure of an in vitro affinityand specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains. J Biol Chem 2002; 277(46): 44021-7 (Pubitemid 36157828)
21. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48(11): 3253-65 (Pubitemid 37409340)
22. Jin X, Ding C. Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis. Expert Opin Biol Ther 2013; 13(2): 315-22
23. Chambers RS. High-throughput antibody production. Curr Opin Chem Biol 2005; 9(1): 46-50 (Pubitemid 40208623)
24. Kenanova V, Olafsen T, Williams LE, et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 2007; 67(2): 718-26 (Pubitemid 46192212)
25. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62(1): 43-52 (Pubitemid 46330791)
26. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41(10): 1133-7 (Pubitemid 35203540)
27. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68(6): 797-804
28. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275-85 (Pubitemid 43736578)
29. Bossaller L, Marshak-Rothstein A. The innate immune system in SLE. In: Wallace DJ, Hahn BH, et al. editors, Dubois' lupus erthematosus and related syndromes. 8th edition, Elsevier, Philadelphia, PA; 2013. p. 75-61
30. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64(5): 625-39
31. Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11(4): R123
32. Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-85 (Pubitemid 351986172)
33. Isaacs J, Olech E, Tak P, et al. Autoantibody-positive rheumatoid arthritis (RA) patients have enhanced clinical response to rituximab when compared to seronegative patients. Ann Rheum Dis 2009; 68(3): 442
34. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3(2): 86-95
35. Bourmans M, Thurlings R, Vos K, et al. Mechanisms of inhibition of joint destruction by rituximab in rheumatoid arthritis. Arthritis Rheum 2010; 62(10): 761
36. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113(20): 4834-40
37. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112(10): 4170-7
38. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012; 8(7): 430-6
39. Burge DJ, Bookbinder SA, Kivitz AJ, et al. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. Clin Ther 2008; 30(10): 1806-16
40. Pfizer. Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis. Available from: Clinical Trialsgov trial number NCT00634933 [Last accessed 10 April 2013]
41. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186(3): 1840-8
42. Ota M, Duong BH, Torkamani A, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010; 185(7): 4128-36
43. Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006; 7(5): 464-72 (Pubitemid 43772987)
44. Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol 2013; 40(5): 579-89
45. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71(8): 1343-9
46. Lin WY, Gong Q, Seshasayee D, et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 2007; 110(12): 3959-67 (Pubitemid 350248451)
47. Lilly. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results Decision not based on safety concern. 2013
48. GlaxoSmithKline. Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis. Available from: ClinicalTrialsgov trial number NCT01077531 2011 [Last accessed 10 April 2013]
49. LLC EPDS. A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active RA Failing Treatment With Methotrexate and TNF-alpha Blocking Agents. Available from: ClinicalTrialgov; trial number NCT00042406 2012
50. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229(1): 307-21
51. Platt AM, Gibson VB, Patakas A, et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185(3): 1558-67
52. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5(3): 443-53 (Pubitemid 40313335)
53. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013; 12(2): 147-68
54. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6(1): 75-92 (Pubitemid 46020288)
55. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200(3): 277-85 (Pubitemid 39031247)
56. Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 2012; 64(1): 21-32
57. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010; 49(11): 2217-19
58. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008; 68(5): 1443-50 (Pubitemid 351346852)
59. Gay RD, Clarke AW, Elgundi Z, et al. Anti-TNFalpha domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs 2010; 2(6): 625-38
60. Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008; 21(5): 283-8
61. Walker A, Dunlevy G, Rycroft D, et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 2010; 23(4): 271-8
62. Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011; 332(6028): 478-84
63. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann NY Acad Sci 2009; 1182: 111-23
64. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11(8): 633-52
65. Sandborg C, Mellins ED. A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367(25): 2439-40
66. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2013; 13(3): 361-76
67. Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011; 12: 153
68. Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. Annu Rev Immunol 2010; 28: 321-42
69. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13(6): 397-411
70. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440(7081): 237-41 (Pubitemid 43372104)
71. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381(9877): 1541-50
72. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5(1): 1-4
73. Sanofi. A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX. Available from: ClinicalTrials.gov 2013
74. Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011; 72(2): 270-81
75. Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71(7): 1183-9
76. von Delwig A, Locke J, Robinson JH, Ng WF. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62(1): 143-9
77. Annunziato F, Cosmi L, Liotta F, et al. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009; 5(6): 325-31
78. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72(6): 863-9
79. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366(13): 1190-9
80. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366(13): 1181-9
81. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62(4): 929-39
82. Mark C, Genovese MWG, Cho CS, et al. A Phase 2 study of multiple subcutaneous doses of LY2439821, an anti-il-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors. ACR/ARHO 11; Chicago: 2011
83. Pavelka K, Yun C, Richard N, et al. A Randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 2012; 64(Suppl 10): 831
84. Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007; 3(8): 434-42 (Pubitemid 47193549)
85. Strunk J, Bundke E, Lange U. Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 2006; 26(3): 252-6 (Pubitemid 41830984)
86. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99(17): 11393-8 (Pubitemid 34920936)
87. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-42 (Pubitemid 38702844)
88. Kanakaraj P, Puffer BA, Yao XT, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; 4(5): 600-13
89. Schwager K, Kaspar M, Bootz F, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009; 11(5): R142
90. Silacci M, Baenziger-Tobler N, Batey S, et al. COVA301: a highly potent bispecific inhibitor of IL17A and TNFa. mAbs 2011; 4(1): 16
91. Fleischmann RM, De Bruyn S, Duby C, et al. A novel individualised treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate. ACR Meeting Report; 2012
92. Maarten Van Roy HU, Rossenu S, Jacobs S, et al. Preclinical development of ALX-0061, an Anti-IL-6R nanobody for therapeutic use in rheumatoid arthritis with a high in vitro affinity and potency and a competitive in vivo pharmacological profile. ACR Meeting Report; 2012
93. Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005; 1(1): 47-54
94. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377(9773): 1276-87
95. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al.Superiority of denosumab to zoledronic acid for prevention of skeletal- related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48(16): 3082-92
96. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58(5): 1299-309 (Pubitemid 351705919)
97. Tarner IH, Muller-Ladner U, Gay S. Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2007; 3(6): 336-45 (Pubitemid 46864888)
98. Lindy S, Uitto J, Turto H, et al. Lactate dehydrogenase in the synovial tissue in rheumatoid arthritis: total activity and isoenzyme composition. Clin Chim Acta 1971; 31(1): 19-23
99. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81(1): 1-5 (Pubitemid 46028489)
100. Tamaki Y, Takakubo Y, Hirayama T, et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 2011; 38(5): 810-20
101. Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48(7): 2052-8 (Pubitemid 36828701)
102. Schierbeck H, Lundback P, Palmblad K, et al. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011; 17(9-10): 1039-44
103. Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005; 366(9479): 50-6 (Pubitemid 40956530)
104. Koffeman EC, Genovese M, Amox D, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009; 60(11): 3207-16
105. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5(8): 577-82 (Pubitemid 47074113)
106. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303(5663): 1532-5 (Pubitemid 38314426)
107. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013; 5(178): 178ra40
108. Lenert P. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol 2010; 161(2): 208-22
109. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9(2): 102-14
110. Nakasa T, Shibuya H, Nagata Y, et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 2011; 63(6): 1582-90
111. Lin HS, Hu CY, Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007; 150(7): 862-72
112. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71(3): 424-31
113. Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004; 50(10): 3365-76 (Pubitemid 39372015)
114. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367(6): 495-507
115. Hirata S, Dirven L, Shen Y, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013
116. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50(5): 1412-19 (Pubitemid 38608062)
117. Greenwald MW, Shergy WJ, Kaine JL, et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 2011; 63(3): 622-32
118. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43(1): 30-7 (Pubitemid 30368210)
119. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183(2): 787-91